SCHEMBL6756745

SCHEMBL6756745

Nc1cc(Cl)cc(NC(=O)/C=C/c2ccccc2Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.66
MAPT P10636 8/20 0.66
NPC1 O15118 6/20 0.66
MAOB P27338 2/20 0.66
MAOA P21397 1/20 0.61
KMT2A Q03164 8/20 0.61
MEN1 O00255 6/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
PKM P14618 1/20 0.61
NFKB1 P19838 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
TP53 P04637 2/20 0.60
THRB P10828 2/20 0.60
KDM4E B2RXH2 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6756742 1.00 RAB9A (0.66) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6756739 1.00 RAB9A (0.66) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6757909 0.85 MAPT (0.74) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6757911 0.85 MAPT (0.74) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6757908 0.85 MAPT (0.74) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6759861 0.84 MAPT (0.59) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6759860 0.84 MAPT (0.59) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6759862 0.84 MAPT (0.59) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6756576 0.84 EGFR (0.51) RAB9AMAPTNPC1MAOBMAOA
SCHEMBL6755624 0.84 MAOB (0.65) RAB9AMAPTNPC1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 RAB9A 1818/4885MAPT 3247/4885NPC1 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.